Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CiVi007 in subjects with elevated LDL-C
NCT03427710Phase 1Completed
- Sponsor
- CiVi Biopharma
- Start
- Feb 2018
- Primary completion
- Feb 2020
- Modality
- Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of civi 007 in hypercholesterolemia (6 arms), sponsored by CiVi Biopharma. Primary endpoint: LDL Cholesterol at 8 weeks. Started Feb 2018; status: completed.
02
Drugs
civi 007
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03427710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03427710.